Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development
about
Chemical Variations on the p53 Reactivation ThemeModulation of Protein-Protein Interactions for the Development of Novel TherapeuticsMolecular docking and structure-based drug design strategies8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 InteractionDesign, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 InteractionFBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine DoubleMDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismGenomic Classification of Cutaneous MelanomaSmall-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Small-molecule MDM2-p53 inhibitors: recent advances.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?New Frontiers in DruggabilityHow To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.Molecular Probing of the HPV-16 E6 Protein Alpha Helix Binding Groove with Small Molecule Inhibitors.AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Potential Therapeutic Targets in Uterine Sarcomas.The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.Radiosensitization of adenoid cystic carcinoma with MDM2 inhibition.Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Identifying the determinants of response to MDM2 inhibition.Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.Reviving the guardian of the genome: Small molecule activators of p53.Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.The Role of MDM2 in Promoting Genome Stability versus Instability.Virtual screening for inhibitors of the human TSLP:TSLPR interaction.A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.Understanding Protein-Protein Interactions: Essential Players in (Patho)physiology (Part 1).The Roles of MDM2 and MDMX in Cancer.Reductive Transformations of Carbonyl Compounds Catalyzed by Rhodium Supported on a Carbon Matrix by using Carbon Monoxide as a Deoxygenative AgentEvolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
P2860
Q26749008-BC003569-6F6D-4905-8B5C-7CA04ED364BDQ26775356-775CAB9A-AFFF-465F-B498-FDF9077BB1BCQ26800097-FAF7EB27-5A86-4F5F-B06F-9B3CB008FFAFQ28547009-FB8F31CC-AAFF-43B1-91FD-4A4EADF105EAQ28548694-369518F8-DFE1-48E2-8BF8-A3A31D0E8D4EQ30176404-699D60C2-B8F5-4675-9FB7-F671C250ED6CQ33572704-18252595-B614-4330-ABDC-C79A805FD822Q33869257-65AB2CBD-278B-460D-8AEA-579CD57B39B3Q34063712-D6787E5E-0BDD-4C69-80EC-862BD27B445EQ34079481-BE02D46C-C74E-40D4-A97A-BCE5F86F1474Q34670776-9CD4E2B9-CFDE-468F-8641-BC2ADAF23824Q35087851-1732ECBB-7AFB-42B7-9805-752D62863725Q35550054-8EACCF6C-229B-4B48-9650-87EE2C88A148Q35617077-B1343438-A8A4-430F-AA06-D70439A20E0CQ35687836-474D5C1A-6674-48FC-ABAB-B8C08B49A380Q35730955-24809114-7D01-45EB-B9B3-2EE8D55574A8Q35871210-1C3F0C4D-0986-4E4B-845D-BC9A43A26DC7Q35874377-ACF8F6E5-EA32-4858-9410-288F36DC640EQ35935872-56852EF3-540F-4456-A102-07298FD284E6Q35997296-A7C88F97-8485-4825-90CC-9E3765C7D77BQ36132787-7EE522EE-0A39-4D7B-8830-D7ABF59F0470Q36245677-0902C116-9FCB-4B2E-AE3B-94149FDA8D69Q38637803-57831F55-E778-4E86-8CEF-2421A9306987Q38703939-4EE97796-2B0A-4DCD-ABED-3A928E87F067Q38749151-3F040E73-157C-429A-9120-1AE896ABD6B6Q38767574-00860257-DEAE-4D63-95EB-254B2B975CD6Q38865504-8F679116-3575-416F-A26D-4020CE84BE40Q38904655-6F0A1EF4-8472-4BA3-9858-B713486479C4Q38988816-0E30D90F-24D6-462D-9C89-4BDF4E7FE52BQ38997002-B016BA9D-B3A7-45BA-B7B2-E77785D4A6A6Q39036213-D9A7FE99-634B-4B08-B6EC-D39F0BACE48DQ39205536-95A53334-EA3D-40E6-9895-EF66877E21DCQ41179373-5020D88D-7210-4C66-9890-1A1E73329D76Q47096280-5BB0B7F7-C855-4F41-9A84-B3FD03C2C9D1Q47133599-1B20F4FF-4D12-46A2-8EFE-55167656A42AQ47152365-59C531FB-195C-46F2-AB58-601B84A9F92FQ52817076-21FFCA49-8462-44C0-A260-E1507A7F2882Q55517350-01EF3125-C66F-40AD-9814-2531385CF85CQ57998768-2E10BFAA-1B9D-4B1B-B96E-73E8D2B8964AQ58697064-FC467053-DFEB-4B09-B426-534F2122E491
P2860
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Discovery of AMG 232, a potent ...... ibitor in clinical development
@ast
Discovery of AMG 232, a potent ...... ibitor in clinical development
@en
Discovery of AMG 232, a potent ...... ibitor in clinical development
@nl
type
label
Discovery of AMG 232, a potent ...... ibitor in clinical development
@ast
Discovery of AMG 232, a potent ...... ibitor in clinical development
@en
Discovery of AMG 232, a potent ...... ibitor in clinical development
@nl
prefLabel
Discovery of AMG 232, a potent ...... ibitor in clinical development
@ast
Discovery of AMG 232, a potent ...... ibitor in clinical development
@en
Discovery of AMG 232, a potent ...... ibitor in clinical development
@nl
P2093
P3181
P356
P1476
Discovery of AMG 232, a potent ...... ibitor in clinical development
@en
P2093
Alexander M Long
Ana Z Gonzalez
Benjamin Fisher
Brian Lucas
Brian M Fox
Daqing Sun
David Chow
Dongyin Yu
Felix Gonzalez-Lopez De Turiso
P304
P3181
P356
10.1021/JM401753E
P407
P50
P577
2014-02-05T00:00:00Z